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ABSTRACT 
Objective: We aimed to delineate the neurodevelopmental spectrum associated with 
SYNGAP1 mutations and to investigate genotype-phenotype correlations.  
Methods: We sequenced the exome or screened the exons of SYNGAP1 in a total of 
251 patients with neurodevelopmental disorders. Molecular and clinical data from 
patients with SYNGAP1 mutations from other centers were also collected, focusing 
on developmental aspects and the associated epileptic phenotype. A review of 
SYNGAP1 mutations published in the literature was also performed. 
Results: We describe 17 unrelated affected individuals carrying 13 different novel 
loss-of-function SYNGAP1 mutations. Developmental delay was the first 
manifestation of SYNGAP1-related encephalopathy; intellectual disability became 
progressively obvious and was associated with autistic behaviors in half of the 
patients. Hypotonia and unstable gait were frequent associated neurological features. 
With the exception of one patient who experienced a single seizure, all patients had 
epilepsy, characterized by falls or head drops due to atonic or myoclonic seizures, 
(myoclonic) absences, and/or eyelid myoclonia. Photosensitivity was frequent. 
Seizures were pharmacoresistant in half of the patients. The severity of the epilepsy 
did not correlate with the presence of autistic features or with the severity of cognitive 
impairment. Mutations were distributed throughout the gene, but spared spliced 3‟ 
and 5‟ exons. Seizures in patients with mutations in exons 4-5 were more 
pharmacoresponsive than in patients with mutations in exons 8-15. 
Conclusion: SYNGAP1 encephalopathy is characterized by early 
neurodevelopmental delay typically preceding the onset of a relatively recognizable 
epilepsy comprising generalized seizures (absences, myoclonic jerks) and frequent 
photosensitivity.
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INTRODUCTION 
The human SYNGAP1 gene on chromosome 6p21.3 encodes the synaptic RAS-
GTPase-activating protein 1, a protein of the post-synaptic density (PSD) of 
glutamatergic neurons [1, 2]. SYNGAP1 interacts with PSD95 (DLG4) and SAP102 
(DLG3), and is able to positively or negatively regulate the density of NMDA and 
AMPA receptors at the glutamatergic synapses and mediate signaling downstream of 
glutamate receptor activation [3, 4]. While complete Syngap1 deficiency in mice is 
lethal at early post-natal stages, heterozygous syngap1+/- mice are viable but show 
behavioral and cognitive disturbances [5, 6, 7, 8]. Syngap1 haploinsufficiency 
disrupts the excitatory/inhibitory balance in the developing hippocampus and cortex 
and results in accelerated glutamatergic synapse maturation. When this process 
occurs during critical developmental windows, it alters the synaptic plasticity 
necessary for the refinement of connections that ultimately shape cognitive and 
behavioral modalities [4, 9]. Different SYNGAP1 protein isoforms exist and are 
generated through alternative splicing and alternative promoter usage, in a process 
regulated by synaptic activity and postnatal age in mice. Two of the main SYNGAP1 
mouse isoforms that differ in their N-terminal and C- terminal sequences, have 
opposite effects on glutamate activation pathway [10]. Although several isoforms 
have also been described in humans, their specific role has not yet been established. 
 
Recently, several groups have independently reported de novo SYNGAP1 mutations 
in patients with intellectual disability (ID), epileptic encephalopathy (EE) or autism 
spectrum disorders (ASD) identified by exome sequencing [11, 12, 13, 14, 15] or 
direct sequencing of the SYNGAP1 gene through a candidate gene approach [16, 17, 
18, 19, 20, 21, 22, 23, 24]. Recently, seven SYNGAP1 mutations were identified by 
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exome sequencing in a series of 1,133 patients, 83% of whom had ID, indicating a 
frequency of SYNGAP1 mutation of 0.74% in patients with ID [25]. One patient with 
a chromosomal translocation interrupting SYNGAP1 [26] and five patients with 
6p21.3 deletions encompassing SYNGAP1 [23, 27, 28, 29, 30] have also been 
reported. Thus, to date, SYNGAP1 appears one of the most relevant ID-causing 
genes, with mutations possibly explaining 0.7 to 1% of ID. Genotype-phenotype 
correlations have not been clearly established. Moreover, because most patients with 
SYNGAP1 mutation were identified in large-scale exome or panel studies, the clinical 
features and the natural history of the SYNGAP1-associated ID and epilepsy remain 
to be precisely described. Here, we have gathered the molecular and clinical data of 
15 unreported and two previously reported patients to investigate in more detail the 
SYNGAP1 mutational and neurodevelopmental spectra. 
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METHODS 
Patients. We analyzed 251 patients with variable neurodevelopmental phenotypes 
including ID, EE and ASD (see Supplementary Methods for details) by exome 
sequencing (n=59) or direct sequencing of genes encoding synaptic proteins (n=192). 
One additional patient had an intragenic SYNGAP1 deletion identified by microarray-
based comparative genomic hybridization (array-CGH). Clinical and molecular data 
of 13 additional patients with SYNGAP1 mutation, identified in 12 other centers, were 
collected: all patients with a mutation introducing a premature termination codon or 
occurring de novo (i.e. proven pathogenic), with the exception of patients with 
genomic deletions encompassing other genes than SYNGAP1, were eligible for 
inclusion. Patients #2 and #10 have been previously reported [12, 24]. Each patient's 
referring physician filled out a table with detailed developmental, neurological, 
behavioral and epileptic medical history, including EEG and imaging data if available. 
Most patients were evaluated according to developmental scales routinely used in 
enrolled centers by clinicians trained in neurodevelopment or neuropsychologists (for 
example Brunet-Lezine, HAWIK-IV, or SON-R2 scales). The sex ratio was 8 males / 
9 females. Mean age at the time of the study was 10.3 years (range 3-29 years). 
Informed written informed consent was locally obtained for all participants. This study 
was approved by INSERM (RBM C12-06) and the ethical CCPRB committee from La 
Pitié-Salpêtrière (Paris, France). 
 
Exome sequencing. The exome of index cases or parent-offspring trios was 
sequenced by IntegraGen (Evry, France) or by the Genotypic and sequencing facility 
of ICM [31]. Exons were captured from fragmented genomic DNA samples using the 
SureSelect Human All Exon 50Mb exome kit (Agilent Technologies) or the SeqCap 
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EZ Solution-Based Enrichment v3.0 (Roche), and paired-end 150-base massive 
parallel sequencing was carried out on an Illumina HiSeq2500 or a NextSeq500, 
according to manufacturers‟ protocols. Bioinformatics analyses were respectively 
done using the in-house pipeline developed by Integragen SA, as previously 
described [31] or by the iCONICS ICM facility platform as follows: sequencing reads 
passing quality filtering were aligned to the human reference genome (hg19) with 
Burrows-Wheeler Aligner (BWA) [32]; GATK [33] was used to recalibrate base quality 
scores, realign around indels, and mark duplicate reads. Variants were filtered based 
on their impact on the gene (missense, nonsense, frameshift, splice site-altering 
variants) and a minor allele frequency lower than 1% in databases (Exome Variant 
Server, 1000 Genomes, HapMap, Exome Aggregation Consortium, and in-house 
databases). Calling of de novo variants in trios was done using the Eris interface 
(Integragen SA) or Polyweb (University Paris-Descartes).  
 
SYNGAP1 screening and Sanger sequencing. All exons and intron-exon junctions 
of SYNGAP1 (NM_006772.2) and 18 other synaptic genes were amplified using the 
Fluidigm Access Array technology (IFC Controller AX, FC1 Cycler, 48x48 Access 
Arrays) and sequenced on a MiSeq Illumina sequencer as paired-end 2 x 250 bp 
reads. Alignment of reads on the human reference was performed with BWA and 
GATK, and additional bioinformatics steps including filtering for novel coding variants, 
were done using an in-house pipeline. Mutations identified by next generation 
sequencing (exome or panel) were validated by Sanger sequencing. De novo 
occurrence was tested by analyzing available parents. The predicted effect of 
mutations was interpreted with Alamut 2.2 (Interactive Biosoftware).  
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SYNGAP1 isoforms and genotype-phenotype correlations. Human SYNGAP1 
cDNA and protein sequences were retrieved from NCBI and Uniprot, aligned using 
Clustalw2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) and compared to mouse and 
rat isoforms [10]. We first assessed genotype-phenotype correlations in the 17 
affected individuals from our cohort.  
Review of individuals with previously published SYNGAP1 mutations. The 
terms „SYNGAP1‟ and „mutation‟ were used to search for articles reporting patients 
with SYNGAP1 mutation in Pubmed. In addition, SYNGAP1 mutations and variants 
present in the HGMD professional (Biobase) and Exac databases were retrieved, 
listed and visualized on the schematic representation of the SYNGAP1 gene. 
Statistical analysis was done using the Fisher exact test. 
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RESULTS 
Genetic analyses and review of SYNGAP1 mutations. In our cohort of 251 patients 
with neurodevelopmental disorders, we identified 3 patients (1.2%) with novel de 
novo pathogenic heterozygous mutations of SYNGAP1 using exome or panel 
sequencing. One additional patient had a SYNGAP1 deletion of 16.6 Kb 
encompassing exons 2-9, identified by array-CGH. We collected additional 
phenotypic information for two cases published previously [12, 24] and 11 additional 
patients with SYNGAP1 mutations identified in other centers (Table 1 and 
Supplementary Table 2).  
SYNGAP1 mutations occurred de novo in all 12 patients for whom DNA of both 
parents was available and, with the exception of one de novo missense mutation, all 
of them introduced a premature termination codon in the protein sequence (Table 1 
and Figure 1). None of the mutations were reported in control databases (Exome 
Variant Server, 1000Genomes, HapMap, Exome Aggregation Consortium). The 
single missense mutation of this study (c.1685C>T, p.Pro562Leu, rs397514670), also 
identified in a previously reported patient [20], altered a highly conserved amino acid 
of the RasGap/GTPase domain of the protein (up to yeast) and was predicted 
damaging by SIFT and Polyphen-2. 
In total, 47 patients (including two monozygotic twins [23]) carrying 43 different point 
mutation or indels limited to the SYNGAP1 gene have been described to date (Figure 
1 and Supplementary Table 3). Three recurrent mutations (c.321_324del, c.427C>T/ 
p.Arg143*, c.1685C>T/ p.Pro562Leu) were found in 2 patients each. Pathogenic 
mutations in SYNGAP1 are distributed throughout the gene, especially in exons 5, 8, 
and 15, which are amongst the largest exons of SYNGAP1. Interestingly, the two first 
and two last exons, which are alternatively spliced and included in 3 out of 5 
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SYNGAP1 isoforms, but also exons 9 and 16, present in all known isoforms seem to 
be spared (Figure 1).  
 
 
Clinical and neurodevelopmental features of SYNGAP1-related encephalopathy 
(Table 1 and Supplementary Table 1). All patients with SYNGAP1 anomalies of our 
series had ID which was evaluated as severe in 10 patients, moderate in five and 
mild in two. The mean age of sitting unsupported was 12 months (median age 10 
months, n=15) and of walking 27.7 months (median age 24 months, n=15). Half of 
the patients could walk by age 2 years and 75% by age 3 years. All patients had 
speech delay: 12 of them spoke first words at a mean age of 2.5 years and five 
patients did not speak at age 10 years or older. In most patients, both receptive and 
expressive languages were affected. Two patients had mild ID, including one without 
motor delay. In those, mild, progressive language delay and behavioral anomalies 
were the most prominent features. 
Eight out of 16 patients (50%) older than 3 years old were diagnosed with ASD. 
Patients with ASD had remarkably poor verbal and non verbal communication 
abilities as well as impaired social interactions (Supplementary Table 1). Half of the 
patients (n=4/8) with severe ID, 1/5 with moderate ID and 2/2 with mild ID were 
diagnosed with ASD. Independent from a formal diagnosis of ASD, many of the 
patients exhibited stereotypies (n=10), temper tantrums, aggressiveness, self- 
injurious behavior and/or restlessness (n=7).  
Neurological examination, performed at a mean age of 8.9 years, was considered 
normal in two patients. Gait was clumsy or unsteady in five patients and ataxic in five 
others. Truncal hypotonia was reported in 10 patients and facial hypotonia in four. 
Some patients had orthopedic problems, such as pes planus and rotation of the hips. 
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Brain MRI performed in all 17 patients (mean age 5.4 years) was either normal or 
revealed nonspecific features (arachnoid cysts in two patients, mild myelination delay 
in one, and signal abnormities in another). 
Epilepsy was diagnosed in 16/17 patients (Table 2). The only patient without epilepsy, 
who was aged 5 at the time of this study, had a single afebrile seizure at the age of 
3.5 years. Excluding this patient, first seizures occurred at a mean age of 3 years 
(range: 1-8 years) and consisted of drop-attacks, massive myoclonic jerks, atonic 
seizures, myoclonic absences or absences. A diagnosis of Doose syndrome (DS) 
and epilepsy with myoclonic absences (EMA) was made in three and one patients, 
respectively. The others were diagnosed with unclassified genetic generalized 
epilepsy (GGE). None had a diagnosis of Lennox-Gastaut syndrome (LGS). 
The epilepsy responded to a single anti-epileptic drug (AED), mostly sodium 
valproate, in seven patients and was pharmacoresistant in nine. During the active 
phases of epilepsy, seizures occurred daily in five patients, 10 times per day or more 
in two and 100 times daily or more in two others. Seizures were of short-duration and 
the most frequent seizure types were typical or atypical absences (n=9), massive 
myoclonic jerks with or without falls (n=7), eyelid myoclonia (n=3), clonic or tonic 
clonic seizures (n=3), myoclonic absences (n=3) and atonic seizures (n=2). Head 
drops or falls were relatively frequent (n=5) and reported as myoclonic-astatic, atonic 
seizures or drop-attacks. Eight patients had several seizure types. No patients had 
status epilepticus and exacerbation by fever was mentioned in four. We found no 
correlations between the diagnosis of ASD and the age at epilepsy onset. The 
proportion of patients with ASD was identical among those with pharmacoresistant 
(n=5/10) and pharmacosensitive epilepsy (n=3/6). 
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The most frequent anomalies reported on EEG traces (Figure 2) from 16 patients 
were ictal or interictal bursts of spikes, spike-waves or slow waves that were either 
generalized (n=13), generalized with a posterior predominance or posterior only 
(n=5). Paroxysmal anomalies were localized to central regions in six instances. 
Triggers of seizures were identified in seven patients, including photosensitivity (PS, 
n=5), fixation-off sensitivity (FOS, n=1), PS and FOS (n=1), and chewing (n=1). 
 
Genotype/phenotype correlations. We observed no definite correlation between 
the location of the mutation on the gene and the severity of ID or ASD diagnosis. 
However, schematic representation of the clinical features of our 17 patients, ordered 
by the position of the mutation on the gene (Figure 3), revealed that the epilepsy of 
patients with mutations in exons 4-5 was mainly pharmacosensitive (5/6 patients) 
whereas that of patients with mutations in exons 8-15 was mainly pharmacoresistant 
(8/9, p=0.01).  
 
DISCUSSION 
In this study, we collected the comprehensive molecular and clinical data of the 
largest series of patients with SYNGAP1 mutation so far in order to describe more 
accurately the neurodevelopmental and epileptic phenotype and to address 
genotype-phenotype correlations. Delineation of the phenotype from 36 patients with 
SYNGAP1 mutations showed that it includes mild to severe ID in all, generalized 
epilepsy in most and autistic behavior in a half of them (Supplementary Table 3). In 
the present study, we describe the phenotype of 17 cases with SYNGAP1-associated 
encephalopathy, bringing the total number of reported patients with SYNGAP1 
mutations to 47. 
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Neurological examination in SYNGAP1-associated encephalopathy. Truncal 
hypotonia, sometimes in association with facial hypotonia, was the main recurrent 
feature in our patients, in line with previous series [20, 23]. Likewise, ataxia, with a 
broad-based or clumsy gait, was frequent in our patients and recurrently mentioned 
in others [20, 23]. Gait abnormalities are probably due to a combination of hypotonia, 
lack of global coordination, poor motor control, inattentiveness and orthopedic issues. 
Occipitofrontal circumference (OFC) was normal in 78% of patients from the literature 
and in 100% of ours. Though microcephaly has been mentioned in some cases [17, 
20, 23], it seems to be not a common aspect in patients with SYNGAP1 mutations. 
As with previously-reported patients, MRI in our patients showed either no or 
nonspecific features, implying that brain imaging is not helpful in the diagnosis of 
SYNGAP1-related disorders. 
 
The neurodevelopmental phenotype in SYNGAP1-associated encephalopathy. 
In our series as well as in the literature, early motor delay with severe language 
impairment is the first manifestation of SYNGAP1 encephalopathy. Fourteen patients 
of our series acquired a few words between 1 and 4 years old but only three patients 
were able to speak simple sentences. These data highlight that language acquisition 
in most patients with SYNGAP1 mutation rapidly reaches a plateau. It may even be 
subjected to regression, since seven of our patients acquired a few words but 
eventually lost them again during the first years of life. 
Slowing of global development and seizures appeared to occur concurrently in some 
patients, suggesting that SYNGAP1 mutation might be a cause of EE, as previously 
suggested [18]. By definition, EE is an epileptic disorder in which the "epileptic 
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activity itself may contribute to severe cognitive and behavioral impairments above 
and beyond what might be expected from the underlying pathology alone" [34]. The 
concept of EE may apply to specific syndromes (West syndrome and LGS) usually 
associated with ID or to epileptic individuals with an encephalopathic course [34]. 
West syndrome and LGS were not diagnosed in our patients. However, retrospective 
analysis of the clinical history of some of them may illustrate an "encephalopathic 
course" apparently related to frequent daily seizures. As an example, patient #14 in 
whom first seizures occurred up to 100 times a day had increasing behavioral 
disturbances and a concomitant stagnation of cognitive acquisition; her language and 
communication skills significantly improved once the epilepsy was controlled. On the 
contrary, the epilepsy of patient #4 responded to sodium valproate alone at 4 years 
old but her cognitive evolution was very poor at 10 years. Beyond these particular 
clinical histories, a global view of the epilepsy and neurodevelopmental disorder in 
our series shows that the level of ID is not related to the resistance or sensitivity of 
the epilepsy to AED (Figure 3). In addition, the age at first seizure does not correlate 
with the resistance to AED and is not clearly linked to the severity of ID. Finally, 
among the eight patients with language regression reported here, two of them only 
had a concomitant first seizure. Epilepsy in the others started several months or 
years after language regression. The contribution of interictal EEG abnormalities to 
cognitive regression is theoretically possible, but cannot be demonstrated since EEG 
were recorded after the first seizure. Consequently, while the concept of EE may 
possibly correspond to the encephalopathic course of a subgroup of patients with 
pharmacoresistant epilepsy in our series, evidence to extend this concept to 
SYNGAP1-related neurodevelopmental disorder in general is lacking. 
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Epilepsy in SYNGAP1-associated encephalopathy. SYNGAP1 mutation rate was 
0.74% in a large series of 940 patients with ID [25], and up to 1% (5/500) in another 
large series of patients with EE [18]. Overall, about 85% patients with SYNGAP1 
mutations had seizures. This suggests that epilepsy is extremely common in the 
SYNGAP1-associated encephalopathy and that SYNGAP1 is one of the most 
frequently mutated genes in patients with ID and epilepsy. All patients in our series 
had generalized seizures, like those reported in a previous study  [20], only a few of 
them also experienced focal clonic or tonic clonic seizures. Generalized bursts of 
spikes, spike-waves and slow waves, sometimes with an occipital predominance, 
were the main recurrent EEG features in our patients. Thus, falls and myoclonic jerks, 
(typical or atypical) absences, sometimes in combination, define the most common 
seizures types that, together with the finding of interictal generalized and/or occipital 
anomalies on EEG, may guide toward the diagnosis of SYNGAP1 mutation in 
patients with ID. 
Though most of our patients with SYNGAP1 mutations had a diagnosis of 
unclassified GGE, seizure types were suggestive of epilepsy syndromes associated 
with ID, particularly EMA and DS, which diagnosis have been suggested in 3 and 1 
patient(s), respectively. To our knowledge, two other patients with EMA were found to 
carry a de novo genetic anomaly affecting SYNGAP1: one with a frameshift mutation 
[20] and another with a gene interruption due to a balanced translocation [26]. 
However, the sequencing of SYNGAP1 in four other patients with EMA and in 
another one with DS failed to reveal any mutations. This result is in agreement with a 
previous work in which a single SYNGAP1 mutation was identified in three patients 
with EMA, 10 with DS and two with LGS [20]. This suggests that SYNGAP1 
mutations are relatively uncommon causes of these epilepsy syndromes. 
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Photosensitivity has been mentioned in previously reported SYNGAP1 patients [17, 
23], but has not been emphasized. The fixation-off phenomenon has been described 
once [24]. In our series, photosensitivity as a trigger for seizure was found in half of 
the patients. Parents or caregivers of four patients noticed it as sensitivity to sunlight, 
artificial light or the television. This high rate of photosensitivity is significant since 
clinical photosensitivity is found in only 10% of patients with epilepsy in the 7-19 
years old group [35]. We assume that photosensitivity may have not been detected in 
some of our patients because it is an age-dependent phenomenon with a peak 
around puberty; it could therefore still appear in some of them; or because of the poor 
cooperation of patients during the recording. These data suggest that 
photosensitivity, when present, might be a diagnostic clue from the EEG of an 
underlying SYNGAP1 mutation. 
 
Genotype/phenotype correlations. Although patients with SYNGAP1 mutations 
show a common core clinical picture, the phenotype is relatively variable, particularly 
regarding the severity of ID, pharmacoresistance and the presence of ASD. Since 
SYNGAP1 is a complex gene, giving rise to several protein isoforms with opposite 
effects on the glutamate activation pathway, via alternative splicing and transcription 
start sites [10], it was tempting to speculate that the location of the mutation on the 
gene could correlate to the clinical outcome. However, we found little correlation 
between the location of the mutation and the severity of ID, epilepsy and/or ASD. Yet, 
the epilepsy of patients with mutations in exons 4-5 appeared more 
pharmacosensitive than that of patients with mutations in exons 8-15. Interestingly, 
exons 4 and 5 are not present in SYNGAP C, an isoform obtained through alternative 
promoter usage, which existence has been demonstrated in mice and rats. Although 
18 
 
this isoform has not been shown to exist in humans as well, our results suggest that it 
could also exist and have a different function, as already proven for isoforms 1 and 
2, which differ in their C-terminus. Further study is necessary to confirm this finding, 
and decrypt the precise function of each human SYNGAP1 isoform and its 
relationship with the human pathology characteristics.  
Nevertheless, the comparison of the clinical features of patients with identical 
mutations revealed significant clinical differences (Supplementary Tables 2 and 3), 
confirming that there is a real variability of the phenotype that depends on other 
factors than the mutation itself. On the contrary, monozygotic twins had strikingly 
similar phenotypes, suggesting that these modifier factors could be of genetic origin 
[23]. 
 
ASD in SYNGAP1-associated encephalopathy and hypothetical consequences 
of SYNGAP1 mutations on brain development. Although all patients with validated 
pathogenic SYNGAP1 mutations reported to date had ID, only half of them had a 
diagnosis of ASD (including data from the literature and our series). In our series, the 
presence of autistic traits was neither limited to patients with moderate or severe ID, 
nor to those with pharmacoresistant or early-onset epilepsy. Thus, ASD, like epilepsy, 
could be considered as an additional feature of the SYNGAP1-related phenotype in 
the context of ID, irrespectively of its severity, rather than an "isolated" diagnosis. 
This observation is in agreement with previous studies showing that many 
neurodevelopmental disorders are caused by mutations in genes encoding synaptic 
proteins, and more specifically constituents of the post-synaptic density [36]. The fact 
that a subset of patients with SYNGAP1 mutations exhibit autistic behaviors suggests 
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that a single mutation in a synaptic gene is not sufficient to cause ASD and that the 
genetic or epigenetic background of the patient probably plays an important role in 
the occurrence of autistic features in a context of intellectual development impairment. 
Many genes mutated in patients with ASD and ID are linked with neuronal signaling 
pathways and may alter the synaptic plasticity underlying the building, refinement and 
consolidation of neuronal networks associated with learning and adaptive behaviors, 
with the balance between inhibitory and excitatory signals being determinant in this 
process [37, 38, 39]. Given the function of the SYNGAP1 protein in regulating 
excitatory inputs downstream of NMDA receptors, the SYNGAP1-associated 
encephalopathy is likely a manifestation of the disruption of this balance. ASD as well 
other neurodevelopmental disorders could in many cases result from the interruption 
or impairment of the maturation processes of neuronal networks that are driven by 
neuronal activity during a critical period of brain development [39]. This scenario is 
particularly relevant to the fact that the clinical and morphological consequences of 
SYNGAP1 haplo-insufficiency in mice, i.e. behavioral disturbances and premature 
dendrite elongation, are restricted to gene disruption during a given period of brain 
development [4, 9]. Following this hypothesis, SYNGAP1 encephalopathy may be 
regarded as an example of premature closing of the time-window for cognitive 
development in humans. In the SYNGAP1-associated encephalopathy, disruption of 
the excitatory/inhibitory balance, which is also a cause of epilepsy, may therefore 
prematurely end the maturation process of synapses and lead to ID, ASD and 
epilepsy by a common pathophysiological mechanism. 
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FIGURE LEGENDS 
Figure 1. Summary of SYNGAP1 mutations identified in this study and the literature. 
(A) Location of mutations on the different SYNGAP1 isoforms. Mutations in red 
correspond to the patients identified in this study. Mutations in black correspond to 
previously published patients. Recurrent mutations are underlined. Isoform 1 
corresponds to the longest isoform (NM_006772.2, N-terminus: SYNGAP A, C-
terminus: SYNGAP 2); isoform 2 is obtained through alternative splicing of exons 18 
and 19 and differs in its C-terminus (SYNGAP : 1265-1343: 
RLMLVEEELR...NGEFRNTADH SPSLQADAGGGGAAPGPPRHG); isoform 3 is 
obtained through alternative transcription start site usage involving an additional exon 
and differs in its N-terminus (SYNGAP B:   1-98: 
MSRSRASIHR…PVEGRPHGEH  MGLRPPTPSP...RRCSSCCFPG); isoform 4 is 
obtained through alternative splicing of exon 19 and differs in its C-terminus 
(SYNGAP : 1296-1343: ERQLPPLGPTNPRV…LQITENGEFRNTADH  LLIR). 
Isoform 5 corresponds to a rat isoform obtained through transcription start site usage 
(SYNGAP C); its existence in humans has not been demonstrated and therefore 
remains putative. Note that other isoforms, not represented on this schematic, have 
been described in rodents but not yet in humans, in particular isoform alpha 1, which 
differs in the C-terminus (QTRV).  (B) Schematic representation of the mutations 
(above) and the variants present in the Exome Aggregation (ExAc) database (below) 
on the longest SYNGAP1 isoform (NM_006772.2) and corresponding protein 
domains. 
 
Figure 2. EEG samples from patients exemplifying electroencephalographic findings 
in SYNGAP1-related encephalopathy. (A) Sample demonstrating normalization of 
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paroxysmal activity by eye opening, i.e. fixation-off sensitivity, in Patient #2. (B) 
Sample showing paroxysmal activity under photic stimulation, i.e. photosensitivity, in 
Patient #2. (C) Sample from Patient #1: burst of generalized spikes concomitant of a 
rapid eye deviation (fast rhythms are due to benzodiazepine therapy). (D) Sample 
from Patient #12 showing the appearance of generalized spike-wave complexes with 
a low degree of bilateral synchronization after eye closure (fixation off phenomenon). 
 
Figure 3. Graphical representation of clinical data (age at epilepsy onset, level of ID 
and pharmacoresistance or pharmacosensitivity) in our patients series. X-axis 
indicates the number of the patient, ordered by the position of the mutation on the 
gene, except patient 1, who corresponds to the patient with the intragenic SYNGAP1 
deletion. Y-axis indicates the age at seizure onset (in months). The proportion of 
patients with mild (circles), moderate (triangles) and severe (squares) ID is not 
different in the pharmacoresistant (red) and in the pharmacosensitive (green) groups. 
One patient (black square, patient 10), who had a single afebrile seizure and was 
thus not considered strictly as epileptic, was not considered for this analysis. The age 
at the first seizure is neither related to the resistance or sensitivity of the epilepsy to 
AED, nor to the position on the gene. The age at seizure onset is not correlated with 
the level of ID. The mutations of most patients with pharmacosensitive epilepsy 
cluster in exons 4-5 whereas those of most patients with pharmacoresistant epilepsy 
spread over exons 8-15 (p=0.001).  
 
SUPPLEMENTARY DATA 
Supplementary Table 1. Additional data to Table 1. 
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Supplementary Table 2. Molecular data of patients with SYNGAP1-associated 
encephalopathy reported in the literature and in the present study. Lines with 
recurrent mutations are highlighted in green. 
Supplementary Table 3. Clinical data of patients with SYNGAP1-associated 
encephalopathy from the literature. Patients reported in two articles [21,30] were not 
included because of insufficient clinical data. 
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Table 1. Molecular and clinical data from the 17 patients with SYNGAP1 mutations*. (1) 
G
e
n
e
ti
c
s
 
Mutation type 
intragenic 
deletion 
nonsense nonsense nonsense frameshift nonsense splice site frameshift frameshift 
Mutation 
c.68-1518-
?_1530+?del 
c.348C>A c.403C>T c.427C>T c.455_459del c.490C>T c.509+1 G>T c.828dup c.1057delC 
Protein level p.? p.Tyr116* p.Arg135* p.Arg143* p.Arg152Glnfs*14 p.Arg164* p.? p.Lys277Glnfs*7 p.Leu353Trpfs*13 
Location in gene intron 1 - exon 9 exon 4 exon 5 exon 5 exon 5 exon 5 intron 5 exon 8 exon 8 
Inheritance de novo de novo de novo de novo de novo de novo de novo parents not tested parents not tested 
Level of intellectual 
disability / Age at 
evaluation 
severe / 10 y mild / 12 y 
moderate / 
5.5 y 
severe / 
10.8 y 
severe / 11 y severe / 11 y moderate / 5 y moderate / 4.5 y moderate / 5.5 y 
D
e
v
e
lo
p
m
e
n
ta
l 
s
ta
g
e
s
 
Age of sitting / 
walking 
7 m / 24 m 10 m / < 18 m 10 m / 20 m 10 m / 24 m 16 m / 36 m 8 m / 20 m 10 m / 22 m 9 m / 15 m NA / 24 m 
Age of first words 
/ first sentences 
4 y / no 
sentences 
14 m / NA 
33 m / no 
sentences 
5 y (5 words) 
/ no 
sentences 
4 y transient "mama" "papa" / 
no sentences 
NA / no sentences 3 y / 5 y 23 m 36 m / no sentences 
Current language 
ability 
single words NA ~ 50 words 10 words absence of speech few words at 11 y 5-word sentences short sentences 15 words 
Regressive 
episode during 
the development / 
Age  
slowing of 
development with 
untreated 
epilepsy / 2y 
no  no no 
possible (loss of few acquired 
words) 
no  
loss of few 
dissylable words 
after 20 m 
no NA 
Autism spectrum 
disorder  
no yes no yes yes yes no no no 
C
li
n
ic
a
l 
E
x
a
m
in
a
ti
o
n
 
Age at 
examination  
14 y 12 y 5.5 y 10.8 y 11 y 10 y 5 y 6 y 5.5 y 
Height in cm 
(SD) / weight in 
kg (SD) / head 
circumference in 
cm (SD) 
133 (-0.5) / 28 (-
0.5) / 50.5 (-1) 
173 (+2.5) / 40 
(-1) / 53 (-1) 
151 (+1) / 53 
(+3) / 53.5       
(-0.5) 
NA 156 (-0.75) / 62 (+0.25) / NA 
143 (+4) / 35 (+3.5) 
/ 51 (-0.5) 
15 (-1.5) / 103 (-1.5) 
/ 49 (-1.5) 
105 (-0.5) / 16 (-1) / 
52 (+0.5) 
110 (-1.5) / 17.9 (-
1.5) / 50.5 (-0.5) 
Neurologic 
examination 
normal normal 
global 
hypotonia, gait 
ataxia 
truncal 
hypotonia 
nystagmus during the 1st year 
(possibly caused by myopia), 
clumsy gait 
facial and truncal 
hypotonia, broad 
based gait 
truncal hypotonia 
facial hypotonia with 
drooling, gait ataxia 
truncal hypotonia, 
walking with 
inwards rotation of 
hips 
 
 
Patient ID 1 2 3 4 5 6 7 8 9 
Age at the time of 
the study (years) 
14 15 8.5 10.8 15 11 5 9.8 5.5 
Sex M F F M F M F F F 
Ancestry Guinean European European European Moroccan Malian European European European 
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Table 1. Molecular and clinical data from the 17 patients with SYNGAP1 mutations*. (2) 
G
e
n
e
ti
c
s
 
Mutation type nonsense nonsense missense nonsense frameshift frameshift frameshift splice site 
nonsense 7; frameshift 
5; splice 2; missense 1; 
intragenic deletion 1 
Mutation c.1253_1254del c.1630C>T c.1685C>T  c.1995T>A c.2214_2217del c.2933del c.3406dup c.3408+1G>A 
Protein level p.Lys418Argfs*54 p.Arg544* p.Pro562Leu  p.Tyr665* p.Glu739Glyfs*20 p.Pro978Hisfs*99 p.Gln1136Profs*17 p.? 
Location in gene exon 8 exon 10 exon 11 exon 12 exon 13 exon 15 exon 15 intron 15 
Inheritance de novo de novo de novo 
parents not 
tested 
de novo de novo parents not tested de novo 
Level of intellectual 
disability / Age at 
evaluation 
severe / 4 y severe / 3 y severe / 22 y severe / 12 y mild / 8 y moderate / 5 y severe / 8.5 y severe / 10 y 
mild n=2; moderate 
n=5; severe n=10 / 
mean age eval. 8.7 y 
D
e
v
e
lo
p
m
e
n
ta
l 
s
ta
g
e
s
 
Age of sitting / 
walking 
15-18 m / 36 m 
12 m / walks only 
with aid 
12 m / 38 m NA / 36 m 8 m / 18 m 10 m / 18 m 16 m / 30 m 25 m / 4.5 y mean 12 m / 27.7 m 
Age of first words 
/ first sentences 
~29 m  transient 
"mama", "papa" / 
no sentences 
3 y "papa" only / 
no sentences 
no words / no 
sentences 
no words / no 
sentences 
12 m / 6 y 3 y / no sentences 
17 m / no 
sentences 
no words / no 
sentences 
mean age first words 
2.6 y 
Current language 
ability 
absence of speech 
absence of 
speech 
absence of 
speech 
absence of 
speech 
120 words, 3 to 4-word 
sentences 
5 words absence of speech 
absence of 
speech 
absence of speech 7; 
speaks words 5; 
associates words or 
simple sentences 3 
Regressive 
episode during 
the development / 
Age  
since age of 36 
months-loss of 
"mama", "papa" 
no 
12m - with febrile 
seizures  
no 14 months no 
loss of words at 
age 18-30 m 
possible (loss of 
2-syllable words) 
n=7 
Autism spectrum 
disorder  
yes 
too young to be 
evaluated 
no no yes no yes yes yes 8; no 8 
C
li
n
ic
a
l 
E
x
a
m
in
a
ti
o
n
 
Age at 
examination 
5.2 y 3 y 22 y 12 y 8 y 7 y 8.5 y 6.6 y mean 8.9 y 
Height in cm (SD) 
/ weight in kg 
(SD) / head 
circumference in 
cm (SD) 
149 (+1.5) / 48.6 
(+2) / 52 (-1.5) 
105 (-0.5) / 20 
(+1.5) / 49.3 (-1) 
93 (0) / 13.8 (0) / 
48 (-2) 
146.5 (+1) / 
35 (+0.5) / 55 
(+1) 
NA /21 (-1) / 54 (+1) 
116 (+1) / 21 (+1) / 
50 (0) 
124 cm (-1.5) / 22 
kg (-1.8) / 50.8 cm 
(-1.7) 
116 cm (+0.4) / 
22.3 kg (+0.7) / 
51.3 cm (+0.4) 
normal OFC 15/15 
Neurologic 
examination 
 truncal hypotonia, 
broad based gait, 
hypotonic-atactic 
movements 
truncal hypotonia, 
swallowing 
difficulties 
mild gait ataxia, 
flexion deformity 
of left hip, 
hyperlordotic 
lumbar spine 
hyperactive 
deep tendon 
reflexes, 
unsteady gait 
motor slowness and 
moderate akinesia, 
ataxic gait, truncal 
hypotonia, dystonic 
postures of hands and 
feet, plastic hypertonia 
truncal hypotonia, 
orthostatic truncal 
tremor, slight 
pyramidal 
tetraparesis, gait 
ataxia 
truncal hypotonia 
truncal hypotonia, 
orofacial 
hypotonia, wide-
based gait 
clumsy/ataxic gait 10, 
truncal hypotonia 10, 
facial hypotonia 4, 
normal exam 2 
* patients are ordered by mutation from the 5‟ end of the gene. NA: not available; m: months; y: years; mean age eval.: mean age at evaluation; SD: standard 
deviation. 
Patient ID 10 11 12 13 14 15 16 17 Summary 
Age at the time of 
the study (years) 
5 3 22 12 8 8.2 29 10 mean 11.4 
Sex M M F M F M M M M=8, F=9 
Ancestry European Iraqi European Turkish European European European  European   
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Table 2. Epilepsy features in SYNGAP1-related encephalopathy. (1) 
 
Patient ID 1 2 3 4 5 6 7 8 9 
Age at seizure onset  
(m:months or 
y:years) 
24 m 24 m 22 m 4 y 3 y 30 m 5 y 33 m 30 m 
Seizure type at 
onset 
myoclonic 
jerks (falls) 
drop attacks 
febrile 
seizure 
GTCS, abs. 
tonic febrile and afebrile, 
myoclonic jerks 
not defined abs. abs. head nodding, abs. 
Seizure types 
during disease 
course 
myoclonic 
abs., eye 
myoclonia 
GTCS, clonic, 
drop attacks, 
myoclonic jerks,  
atypical 
abs., 
myoclonic 
jerks, atonic 
seizures 
abs. 
head falls, massive myoclonic 
jerks of arms, myoclonic abs. 
abs. abs. abs. 
myoclonic jerks 
(mainly arms) 
Epilepsy syndrome EMA 
DS then atypical 
GGE 
unclassified 
GGE 
unclassified GGE 
with absences 
unclassified GGE 
unclassified GGE 
with absences 
unclassified GGE 
with absences 
unclassified GGE 
with absences 
unclassified GGE 
with absences 
Febrile seizures no yes yes no rare no no no no 
Status epilepticus no no no no no no no no no 
Frequency of 
seizures 
>10 daily then 
2/day 
presently 
nearly seizure-
free 
daily -> one per 
week-> almost 
seizure free 
1-2/month 
seizure free for 
several years 
controlled <1/day several/day daily up to 100/day 
Lifetime / current 
anti-epileptic 
treatment 
VPA VPA then LEV LEV VPA 
VPA, OXC, LTG, LEV, CBZ / 
VPA + LTG 
VPA, CBZ LTG VPA, LTG / LTG 
VPA, ETH, LEV, 
CLN*, ketogenic 
diet / none 
Pharmoresistance no no no no partial no no yes yes 
E
E
G
 
Age at 
examination 
9 y 2 to 15 y 4.5 y 9 y 1 to 5 y 3 to 8 y 5 y 8.5 y 5 y 
Main 
abnormalities 
generalized 
bursts of S 
generalized 
PsW and 
photoconvulsion
s 
frontal and 
generalized 
SpW and 
PSW 
irregular spike-
slow-wave-
complexes: 
generalized, 
maximum frontal; 
beta-waves 
1 y: normal; 3.5 y: generalized 
bursts of S, S + SW in 
posterior areas; 5 y: slow 
background activity, fronto-
temporal bursts of SW 
bi-occipital SW, S 
and SpW, bi-
central anomalies 
NA 
diffuse SpW, PSp or 
PSW 
bursts of bilateral S 
and  PSp with 
maximum in 
posterior regions 
Triggers of 
seizures 
none PS no none none none NA none chewing, emotions 
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Table 2. Epilepsy features in SYNGAP1-related encephalopathy. (2) 
 
Patient ID 10 11 12 13 14 15 16 17 Summary 
Age at seizure onset  
(m:months or 
y:years) 
one seizure at 3.5 
y 
24 m 12 m <2 y 5 y 22 m 27 m 8 y 
mean 35.4 m, median 
age 28.5 m, 75th centile 
39 m 
Seizure type at 
onset 
non febrile febrile  seizure febrile seizures 
astatic 
seizures 
eyelid myoclonia atonic myoclonic seizures NA   
Seizure types 
during disease 
course 
NA eyelid myoclonia 
eyelid 
myoclonia, 
atypical abs., 
myoclonic jerks 
myoclonic 
astatic 
eyelid myoclonia, 
myoclonic abs. 
GTCS, focal, 
atypical abs., 
myoclonic jerks 
 myoclonic jerks, 
GTCS, atypical 
abs. 
atypical absences 
myoclonic jerks 7, 
atypical abs. 5, abs. 4, 
eyelid myoclonia 3, clonic 
or GTCS 3, myoclonic 
abs.3, atonic 2 
Epilepsy syndrome NA unclassified GGE 
unclassified 
GGE 
DS unclassified GGE DS unclassified GGE unclassified 
unclassified 12 , DS 3, 
EMA 1 
Febrile seizures no yes yes no no no no no yes 4 
Status epilepticus no no no no no 
clusters of 
seizures/no status 
epilepticus 
no no n=0 
Frequency of 
seizures 
only one until 
now 
several/day several/month 10/day 100/day several/day several/day 4-8/month   
Lifetime / current 
anti-epileptic 
treatment 
no VPA LEV, TPM 
VPA, ZNM, 
LTG 
LEV, ETH 
VPA, LTG + VPA, 
LTG, LEV, CLN, 
ACTH 
VPA, CBL, TPM / 
ketogenic diet 
VPA   
Pharmoresistance not applicable no yes yes  yes yes yes partial yes 9, no 7 
E
E
G
 
Age at 
examination 
1.8 and 2.5 y 3 y 3 to 8 y 2 to 10 y 2 to 5 y 7 8.5 y 2.3 y   
Main 
abnormalities 
1st: SW; 2nd: no 
abnormalities 
abnormal 
background, 
generalized slowing, 
recorded seizures 
with eyelid myoclonia 
and generalized 
seizure patterns 
bursts of S and 
SW in the 
occipital region 
after eye 
closure 
generalized 
SpW 
2y: normal; 5y: ictal 
bursts of diffuse PSW 
with posterior 
predominance after 
eyes closer and 
photic stimulation 
focal SpW in 
central-parietal 
areas, generalized 
S and PSW 
generalized PSW 
and frontal Sw 
multifocal SW   
Triggers of 
seizures 
none PS FOS PS PS, FOS none none PS 
PS 4, FOS 1, PS + FOS 
1, other 1 
 
GTCS: generalized tonic-clonic seizures; abs.: absences; EMA: epilepsy with myoclonic absences; GGE: genetic generalized epilepsy; DS: Doose syndrome. 
Anti-epileptic drugs: VPA: valproic acid, LEV: levetiracetam, ETH: ethosuximide, OXC: oxcarabzepine, CBZ: clobazam, ZNM: zonisamide, LTG: lamotrigin, TPM: 
topiramate, CLN: clonazepam, ACTH: adrenocorticotropic hormone. EEG: electroencephalogram; SW: slow waves; S: spikes; SpW: spike-waves; PSW: 
polyspike-waves; PSp: polyspikes; PS: photosensitivity; FOS: fixation off sensitivity. 
*epilepsy aggravated 
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Figure 1. 
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Figure 2 
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Figure 3. 
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Supplementary Methods. 
Clinical characteristics of the 251 patients with variable neurodevelopmental phenotypes included in this study (ID: intellectual disability, ASD: 
autism spectrum disorder). 
 
Among epileptic patients, 158 had a non-syndromic or unclassified epilepsy. The epilepsy type or the main seizure type in the 58 other 
patients were the following: West syndrome (n=24), epilepsy with myoclonic absences (n=5), Doose syndrome/ epilepsy with myoclonic atonic 
seizures (n=1), malignant migrating partial seizures of infancy (n=1), unspecified neonatal epileptic encephalopathy (n=7), myoclonic epilepsy 
(n=4), absence epilepsy (n=3), generalized epilepsy with tonic-clonic seizures (n=13). 
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Supplementary Table 1. Complement to genetic and clinical data of the 17 patients with SYNGAP1 mutations. (1) 
Patient ID 1 2 3 4 5 6 7 8 9 
G
e
n
e
ti
c
s
 
Family history none 
cousin with 
absence epilepsy 
none none none  none  none  none  none  
Parental age at 
birth 
Mo=35, Fa=18 NA Mo=34, Fa=35 Mo=40, Fa=36 Mo=40, Fa=47 NA Mo=40, Fa=30 Mo=28, Fa=28 NA 
Other 
significant 
genetics 
abnormalities 
none none 
array-CGH: Xp22.33 
dup 491 kb - 511 kb 
(inherited from 
healthy father) 
de novo VOUS: 
RANBP2: c.8146G>A 
(p.K2716E); KLHL8: 
c.95C>G (p.S32L) 
variant in MBD5 
inherited from one 
parent 
none none none 
RBFOX1-deletion 
(hq19 
chr16:6340454-
6814185) 
Method of 
molecular 
diagnosis 
microarray 
analysis 
CeGat panel CeGat panel WES SYNGAP1 testing WES 
panel 
(genetikum ® ) 
SYNGAP1 testing CeGat panel 
N
e
o
n
a
ta
l 
p
e
ri
o
d
 
Pregnancy and 
delivery 
probably 
normal, 
fullterm 
unremarkable Apgar 8/10/10 
unremarkable, 
cesarean section week 
39, Apgar scores 10/10 
unremarkable 
twin pregnancy, 
born at 8 months, 
delivery 
unremarkable 
unremarkable 
mild gestational 
diabetes, fullterm, 
Apgar 10 
unremarkable 
Birth length in 
cm (perc) / 
weight in g 
(perc) / head 
circumference 
in cm (perc) 
NA 
52 (50th) / 3010 
(50th) / 34 (25th) 
55 (90th) / 4125 
(96th) / 36.5 (98th) 
49 (10-50th) /3160 (10-
50th)/ 34 (10-50th) 
50 (10-50th) / 3230 
(10-50th) / 34.5 
(10-50th) 
NA / 2740 (NA) / 34 
(NA) 
52 / 3880 / 36 
48 (10th) / 3300 (25th) / 
33 (25th) 
48 (10th)/ 3420 
(10-50th) / NA 
Neonatal 
findings 
NA none none 
muscular hypertonia 
during first months 
none none none none none 
A
u
ti
s
m
 s
p
e
c
tr
u
m
 d
is
o
rd
e
r 
Alteration of 
nonverbal 
communication 
mild mild moderate no moderate severe NA mild severe 
Repetitive 
behaviours 
no no no yes yes yes little no no 
Stereotypies no no no yes yes yes no yes no 
Social 
interactions 
normal 
no social 
reactions to 
peers, lack of 
eye-contact, no 
empathy 
altered normal very poor very poor altered altered altered 
Behaviour 
troubles 
temper tantrum 
then peaceful 
behaviour 
aggr. especially 
after acoustic or 
tactile stimuli 
severe social anxiety hetero- / autoagr. anxiety restlessness, aggr. 
autoaggr., 
temper tantrum 
temper tantrum, 
occasional aggr. 
anxiety, 
incontrolled panic 
attacks 
Brain imaging (age) normal (9 y) normal (13 y) normal (3.8 y) 
myelination not yet 
complete (4 y) 
normal (2 and 9 y) 
normal with small 
cyst in the right 
pontocerebellar 
angle 
normal (2 y) normal (4 y) normal (3 y) 
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Supplementary Table 1. Complement to genetic and clinical data of the 17 patients with SYNGAP1 mutations. (2)  
Patient ID 10 11 12 13 14 15 16 17 
G
e
n
e
ti
c
s
 
Family history none none none none none none none none 
Parental age at 
birth 
Mo=34, Fa=35 Mo=46, Fa=38 NA Mo=30, Fa=33 
Mo=26, 
Fa=26 
Mo=31, Fa=27 Mo=37, Fa=40 Mo=31, Fa=28 
Other 
significant 
genetics 
abnormalities 
none 
VOUS inherited from 
the mother: SCN9A: 
c.4282G>A and 
c.5624G>A, ARX 
c.1462A>G 
none none none none 
array-CGH: 3q12.2-12.3 
dup 1.55-1.60 MB 
(inherited from healthy 
father) 
none 
Method of 
molecular 
diagnosis 
WES CeGaT panel WES WES WES MIP gene panel CeGaT panel MR-Panel (Kingsmore Panel) 
N
e
o
n
a
ta
l 
p
e
ri
o
d
 
Pregnancy and 
delivery 
unremarkable 
pathologic, otherwise 
normal delivery, 
Apgar 10/10 
IVF; emergency 
LSCS at 36 
weeks due to 
reduced fetal 
movements 
unremarkable unremarkable 
born at 37 WG, 
premature detachment of 
the placenta, Apgar 10 
gestation diabetes, Apgar 
9/10/10  
36+6 week of pregnancy, APGAR 
8/8/8, intensive care 
Birth length in 
cm (perc) / 
weight in g 
(perc) / head 
circumference 
in cm (perc) 
49 (10th) /3160 
(25th) / 36 (50th) 
NA 
47 (50th) / NA / 
NA 
50 (50th) / 3500 
(50th) / 34 (10-
50th) 
49 (10-50th) / 
3120 (10-
50th) / 34 
(10-50th) 
52 (90-97th) / 2700 (25th) 
/33 (10th) 
49 (14th) / 3350 (46th) / 
35 (52th) 
47.5 (<10th) / 2490 (50th) / 33,5 
(>50th) 
Neonatal 
findings 
none none 
slow to suck and 
feed 
none none hyperbilirubinemia none 
hypotonia, bradycardia, 
hypothermia, hyperbilirubinemia 
A
u
ti
s
m
 s
p
e
c
tr
u
m
 
d
is
o
rd
e
r 
Alteration of 
nonverbal 
communication 
moderate-severe moderate-severe  moderate moderate NA NA severe severe 
Repetitive 
behaviours 
no yes no no NA NA yes yes 
Stereotypies yes yes yes no yes yes yes yes 
Social 
interactions 
very poor very poor altered altered NA NA very poor poor 
Behaviour 
troubles 
hetero- / 
autoaggr. 
NA NA aggr. NA NA auto- and hetero-aggr. altered 
Brain imaging (age) 
arachnoid cysts 
(1.8 y) 
normal (3 y) normal (8 y) normal (8 y) normal (5 y) 
slight dilatation of the 
anterior horns of lateral 
ventricles (3 and 5 y) 
normal (28 m and 
6 y)  
bilateral T2 hypersignal of 
fasciculus longitudinalis medialis, 
piritrigonal white matter and 
central parts of centrum 
semiovale (15 m) 
Mo: mother; Fa: father; VOUS: variant of unknown signification; WES: whole exome sequencing; ID: intellectual deficiency; NA: not available; m: months; y: 
years; aggr.: aggressiveness; SD: standard deviation; WG: weeks of gestation; IVF: in vitro fertilization; LCSC: lower segment Caesarean section. 
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Supplementary Table 2. Molecular data of patients with SYNGAP1 encephalopathy reported in the literature and in the present study. 
Type Mutation nomenclature 
(GRCh37) 
Exon Isoform Domain Expected 
effect 
Mutation 
type 
Base change 
(NM_006772.2) 
Amino acid change Inheritance Patient ID Reference 
Point Chr6:g.33393668dup 3 1, 2, 4  Hap frameshift c.283dup p.His95Profs*5 Mosaic father Patient 1 Berryer et al,  2013 
Point Chr6:g.33399963_33399966del 4 1, 2, 3, 4   Hap frameshift c.321_324del p.Lys108Valfs*25 de novo R0038372 Hamdan et al., 2011 
Point Chr6:g.33399963_33399966del 4 1, 2, 3, 4   Hap frameshift c.321_324del p.Lys108Valfs*25 de novo T19988 Carvill et al., 2013 
Point Chr6:g.33399975del 4 1, 2, 3, 4  Hap frameshift c.333del p.Lys114Serfs*20 de novo 217-14271-3940 O'Roak et al., 2014 
Point Chr6:g.33399990C>A 4 1, 2, 3, 4  Hap nonsense c.348C>A p.Tyr116* de novo Patient #2 von Stüpnagel et al., 2015; 
this study 
Point Chr6:g.33400460A>T intron 4 1, 2, 3, 4  Hap splice c.388-2A>T p.? de novo T15924 Carvill et al., 2013 
Point Chr6:g.33400477C>T 5 1, 2, 3, 4  Hap nonsense c.403C>T p.Arg135* de novo Patient #3 This study 
Point Chr6:g.33400486A>T 5 1, 2, 3, 4  Hap nonsense c.412A>T p.Lys138* de novo R0033401 Hamdan et al., 2009 
Point Chr6:g.33400501C>T 5 1, 2, 3, 4   Hap nonsense c.427C>T p.Arg143* de novo T22387 Carvill et al., 2013 
Point Chr6:g.33400501C>T 5 1, 2, 3, 4   Hap nonsense c.427C>T p.Arg143* de novo Patient #4 This study 
Point Chr6:g.33400505_33400508del 5 1, 2, 3, 4  Hap frameshift c.431_434del p.Thr144Serfs*29 de novo 259214 Parker et al., 2015 
Point Chr6:g.33400529_33400533del 5 1, 2, 3, 4 PH Hap frameshift c.455_459del p.Arg152Glnfs*14 de novo Patient #5 This study 
Point Chr6:g.33400564C>T 5 1, 2, 3, 4 PH Hap nonsense c.490C>T p.Arg164* de novo Patient #6 This study 
Point Chr6:g.33400583G>A 5 (last 
nucleotide) 
1, 2, 3, 4 PH Hap missense 
+splice 
c.509G>A p.Arg170Gln de novo 259840 Parker et al., 2015 
Point Chr6:g.33400584G>T intron 5 1, 2, 3, 4 PH Hap splice c.509+1 G>T p.? de novo Patient #7 This study 
Point Chr6:g.33402928G>A intron 5 1, 2, 3, 4 PH Hap splice c.510-1G>A p.? de novo Patient 16 De Ligt et al., 2012 
Point Chr6:g.33403326G>A 7 All PH mis missense c.698G>A p.Cys233Tyr de novo 12804.p1 O'Roak et al., 2014 
Point Chr6:g.33405482G>A 8 All C2 Hap nonsense c.800G>A p.Trp267* de novo T15923 Carvill et al., 2013 
Point Chr6:g.33405510dup 8 All C2 Hap frameshift c.828dup p.Lys277Glnfs*7 NA Patient #8 This study 
Point Chr6:g.33405662T>C 8 All C2 mis missense c.980T>C p.Leu327Pro de novo LEM300468 + 
LEM300469 
Parker et al., 2015 
Point Chr6:g.33405725_33405726del 8 All C2 Hap frameshift c.1043_1044del p.Val348Alafs*70 de novo Patient 8 Vissers et al., 2010 
Point Chr6:g.33405739del 8 All C2 Hap frameshift c.1057del p.Leu353Trpfs*13 NA Patient #9 This study 
Point Chr6:g.33405766T>A 8 All C2 mis missense c.1084T>A p.Trp362Arg de novo Patient 2 Berryer et al,  2013 
Point Chr6:g.33405935_33405936del 8 All RASGAP Hap frameshift c.1253_1254del p.Lys418Argfs*54 de novo ER53899 and 
Patient #10 
Rauch et al., 2012; this 
study 
Point Chr6:g.33406572_33406575del 10 All RASGAP Hap frameshift c.1552_1555del p.Tyr518Asnfs*8 de novo 259041 Parker et al., 2015 
Point Chr6:g.33406650C>T 10 All RASGAP Hap nonsense c.1630C>T p.Arg544* de novo Patient #11 This study 
Point Chr6:g.33408514C>T 11 All RASGAP mis missense c.1685C>T p.Pro562Leu de novo Patient 3 Berryer et al,  2013 
Point Chr6:g.33408514C>T 11 All RASGAP mis missense c.1685C>T p.Pro562Leu de novo Patient #12 This study 
Point Chr6:g.33408564C>T 11 All RASGAP Hap nonsense c.1735C>T p.Arg579* de novo R0032180 Hamdan et al., 2009 
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Point Chr6:g.33408612del 11 All RASGAP Hap frameshift c.1782del p.Leu595Cysfs*55 de novo 212-21043-1 O'Roak et al., 2014 
Point Chr6:g.33408652_33408653del 11 All RASGAP Hap frameshift c.1823_1824del p.Phe608Trpfs*9 de novo 13073.p1 O'Roak et al., 2014 
Point Chr6:g.33409031T>A 12 All RASGAP Hap nonsense c.1995T>A p.Tyr665* NA Patient #13 This study 
Point Chr6:g.33409140C>T 12 All RASGAP Hap nonsense c.2104C>T p.Gln702* de novo T2528 Carvill et al., 2013 
Point Chr6:g.33409426del 13 All RASGAP Hap frameshift c.2184del p.Asn729Thrfs*31 de novo Patient 5 Berryer et al,  2013; 
Dyment et al, 2015 
Point Chr6:g.33409454_33409455del 13 All  Hap frameshift c.2212_2213del p.Ser738* de novo Patient 4 Berryer et al,  2013 
Point Chr6:g.33409456_33409459del 13 All  Hap frameshift c.2214_2217del p.Glu739Glyfs*20 de novo Patient #14 This study 
Point Chr6:g.33409537G>A intron 13 All  Hap splice c.2294+1G>A p.? de novo R0034526 Hamdan et al., 2011; Xiong 
et al., 2015 
Point Chr6:g.33410767del 15 All SH3 Hap frameshift c.2438del p.Leu813Argfs*23 de novo R0033475 Hamdan et al., 2009 
Point Chr6:g.33410959dup 15 All  Hap frameshift c.2630dup p.Thr878Aspfs*60 de novo BO14/09 Rauch et al., 2012 
Point Chr6:g.33411006del 15 All  Hap frameshift c.2677del p.Gln893Argfs*184 de novo R0034759 Hamdan et al., 2011 
Point Chr6:g.33411093C>T 15 All  Hap nonsense c.2764C>T p.Arg922* de novo 264135 Parker et al., 2015 
Point Chr6:g.33411103del 15 All  Hap frameshift c.2774del p.Leu925Profs*152 de novo 259606 Parker et al., 2015 
Point Chr6:g.33411111C>T 15 All  Hap nonsense c.2782C>T p.Gln928* de novo 258913 Parker et al., 2015 
Point Chr6:g.33411262del 15 All  Hap frameshift c.2933del p.Pro978Hisfs*99 de novo Patient #15 This study 
Point Chr6:g.33411606C>T 15 All  Hap nonsense c.3277C>T p.Gln1093* de novo Pat. 8 "258536" Parker et al., 2015 
Point Chr6:g.33411735dup 15 All  Hap frameshift c.3406dup p.Gln1136Profs*17 NA Patient #16 This study 
Point Chr6:g.33411738G>A intron 15 All  Hap splice c.3408+1G>A p.? de novo Patient #17 This study 
Point Chr6:g.33414346G>A intron 16 All CC Hap splice c.3583-6G>A p.Val1195Alafs*27 de novo APN-139 Redin  et al., 2014 
                        
Type Mutation nomenclature 
(GRCh37) 
Type    Size Genes altered Consequence Inheritance  Reference 
CNV Chr6:33389736-33406339 Deletion All PH, C2, 
RASGAP 
Hap 16.6 Kb SYNGAP1 
(intron 1 - exon 
9) 
p.? de novo Patient #1 This study 
CNV Chr6:33356364-33406339 Deletion All PH, C2, 
RASGAP 
Hap 50 Kb SYNGAP1 
(5'UTR-exon 9) 
+ 3 others 
p.? de novo Case report Writzl et al., 2013 
CNV Chr6:33291871-33404064 Deletion All PH, C2, 
RASGAP 
Hap 112 Kb SYNGAP1 
('UTR-intron8) 
+ 5 others 
absence of protein 
synthesis 
de novo Case report Pinto et al., 2010 
CNV NA Deletion All All Hap 300 Kb Entire gene + 6 
others 
absence of protein 
synthesis 
de novo Case report Zollino et al., 2011 
CNV Chr6:33201710-33595089 Deletion All All Hap 393 Kb Entire gene + 
18 others 
absence of protein 
synthesis 
de novo Case report Parker et al., 2015 
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CNV Chr6:33273955–34086729 Deletion All All Hap 813 Kb Entire gene + 
18 others 
absence of protein 
synthesis 
de novo Case report Krepischi et al., 2010  
CNV t(6;22)(p21.32;q11.21) Balanced 
translocation 
    Interrupts 
SYNGAP1 
p.? de novo Case report Klitten et al., 2013 
Hap: haploinsufficiency. 
 
 
Reference
Patient 259041 259840 258913 264135
Sex F F F F
Age (in years) 7 8 7 3
Developmental/neur
ological evaluation
Evaluation of 
developmental 
delay/intellectual 
disability
moderate moderate moderate moderate
Age of sitting 20 m 7 m 12 m 24 m
Age of walking 24 m 36 m 60 m does not walk
Evaluation of 
speech
50 words, two-word 
sentences
single words single words no speech
Neurological signs unsteady gait wide-based gait wide-based gait NA
OFC -1.6 SD + 0.8 SD - 2.6 SD - 2.5 SD
Behavior
aggressiveness, 
routine-orientated
autism, 
aggressiveness, 
routine-orientated, 
obsessions
aggressiveness, 
routine-orientated, 
stereotypies
autism, 
aggressiveness, 
obsessions
Brain MRI NA normal normal normal
Epilepsy no epilepsy yes yes yes
Epilepsy onset NA 6 y 2 y 2 y
Seizure types NA mj, abs mj, abs, drop at abs, drop at
Epilepsy outcome NA NA NA NA
EEG NA NA NA NA
EEG: DS= diffuse slowing; ETPs= epileptic potentials;  GPSW= generalized poly spike waves; GSW= generalized spike waves; MFD= multi focal discharges; GS=generalized spikes; GSW=slow waves; poly-SW= poly spike waves; SSW= slow spike waves  
NA=not available or not applicable; F= female;  M=male; m= months; y=years; ADHD= attention deficit hyperactivitiy disorder; ASD = autistic spectrum disorder; EE= epileptic encephalopathy; EEG= electro encephalogram; mod.= moderate; MRI= magnetic resonance imaging; TPM = topiramate; VPA = valproic acid; OFC=occipitofrontal
Seizures: a = aura; abs = absences; atyp abs = atypical absences; drop at = drop attacks; FDS = focal discognitive seizures; FS = febrile seizures; GTCS = generalized tonic clonic seizures; myo abs = myoclonic absence; myo at = myoclonic atonic; mj = myoclonic jerks; PCS = partial complex seizures; tc = tonic-clonic; PS: photosensitivity
Parker et al. Am J Med Genet 2015
Supplementary Table 3
259214 259606 258536  Pat. 8 "258536" LEM300469
M F F F M
8 12 5 8 14
moderate moderate moderate moderate severe
15 m NA 7 m 12 m 24-36 m
17 m 24 m 19 m 30 m > 60 m
200 single words 20 single words 2-word sentences 4-word sentences absent
NA wide-based gait unsteady gait NA ataxic gait
- 1.1 SD - 1.83 SD - 2.9 SD 0 SD - 0.98 SD
autism, 
aggressiveness, 
obsessions
aggressiveness, 
stereotypies
autism, 
aggressiveness, 
obsessions
ASD
autism, laughter 
outbursts, routine-
orientated, 
obsessions
normal normal NA NA normal
no epilepsy yes no epilepsy yes yes
NA 3 y NA 5 y 13 m
NA
head drops & 
blinking, PS
NA abs, drop at
FS, abs, drop at, 
occasional tc, mj
NA NA NA NA NA
NA NA NA NA NA
EEG: DS= diffuse slowing; ETPs= epileptic potentials; GPSW= generalized poly spike waves;  GSW= generalized spike waves; MFD= multi focal discharges; GS=generalized spikes; GSW=slow waves; poly-SW= poly spike waves; SSW= slow spike waves  
NA=not available or not applicable; F= female; M=male; m= months; y=years; ADHD= attention deficit hyperactivitiy disorder; ASD = autistic spectrum disorder; EE= epileptic encephalopathy; EEG= electro encephalogram; mod.= moderate; MRI= magnetic resonance imaging; TPM = topiramate; VPA = valproic acid; OFC=occipitofrontal
Seizures: a = aura; abs = absences; atyp abs = atypical absences; drop at = drop attacks; FDS = focal discognitive seizures; FS = febrile seizures; GTCS = generalized tonic clonic seizures; myo abs = myoclonic absence; myo at = myoclonic atonic; mj = myoclonic jerks; PCS = partial complex seizures; tc = tonic-clonic; PS: photosensitivity
Parker et al. Am J Med Genet 2015
Redin et al. J Med 
Genet 2014
LEM300468 APN-139 T15923 T22387 T19988 T15924 T2528
M M F F M M M
14 6 26 7 18 11 26
severe moderate severe severe moderate severe moderate
24-36 m delayed NA NA NA NA NA
> 60 m delayed NA NA NA NA NA
absent absent NA NA NA NA NA
ataxic gait
hypotonia, 
cerebellar 
syndrome
NA NA NA NA NA
- 1.2 SD NA NA NA NA NA NA
autism, laughter 
outbursts, routine-
orientated, 
obsessions
stereotypic 
movements, hetero 
and auto-
aggressiveness
ASD ASD NA ASD NA
normal NA NA NA NA NA NA
yes NA yes yes yes yes yes
13 m NA 36 10 NA 6 18
FS, abs, drop at, 
occasional tc, mj
NA
atyp abs, a, 
FDS, mj
abs, mj FDS abs, tc
FS; abs, a, 
FDS, mj, tc, 
NCS
NA NA EE EE EE EE EE
NA NA SSW, MFD GSW MFD, DS
GSW, MFD, 
GPSW
SSW, 
bioccipital 
ETPs, DS
EEG: DS= diffuse slowing; ETPs= epileptic potentials;  GPSW= generalized poly spike waves;  GSW= generalized spike waves; MFD= multi focal discharges; GS=generalized spikes; GSW=slow waves; poly-SW= poly spike waves; SSW= slow spike waves  
NA=not available or not applicable; F= female;  M=male; m= months; y=years; ADHD= attention deficit hyperactivitiy disorder; ASD = autistic spectrum disorder; EE= epileptic encephalopathy; EEG= electro encephalogram; mod.= moderate; MRI= magnetic resonance imaging; TPM = topiramate; VPA = valproic acid; OFC=occipitofrontal 
Seizures: a = aura; abs = absences; atyp abs = atypical absences; drop at = drop attacks; FDS = focal discognitive seizures; FS = febrile seizures; GTCS = generalized tonic clonic seizures; myo abs = myoclonic absence; myo at = myoclonic atonic; mj = myoclonic jerks; PCS = partial complex seizures; tc = tonic-clonic; PS: photosensitivity
Parker et al. Am J Med Genet 2015 Carvill et al. Nat Genet 2013
de Light et al. 
New Engl J 
Med 2012
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 16
Patient 1 
R0034759
F M F M F M F
16 3.5 4.3 2.5 9.3 7.7 3.7
moderate moderate mild moderate
moderate/seve
re
moderate
moderate/seve
re
6 m NA NA 9 m NA 12 m NA
10.5 m 30 m 15 m 21 m 26 m 22 m 22 m
impaired absent delayed absent impaired absent absent
none hypotonia none hypotonia ataxic gait NA hypotonia
normal normal normal "microcephaly" normal normal normal
recurrent 
seasonal 
depression
ASD
autism, 
irritability, 
automutilations
, sleeping 
difficulties
sleeping 
difficulties and 
aggressiveness
ASD
self-mutilation, 
inappropriate 
laughters
attention 
deficit; 
aggressive 
adverse 
behavior
normal normal NA normal normal normal normal
yes yes no epilepsy yes yes yes yes
18 30 NA 36 38 60 29
myo abs, abs, 
mj
drop at, abs NA NA drop at, abs NA head drop, abs
poor control poor control NA NA good control NA good control
GSW posterior 
predominance
GSW posterior 
predominance
"intermittent 
and slow 
dysfunction in 
the
occipital 
regions"
bursts of GS + 
GSW
bioccipital 
predominance
"abnormal 
bursts, in the 
right vertex 
region, of 
poorly
formed waves 
during sleep"
NA
GSW posterior 
predominance
NA=not available or not applicable; F= female;  M=male; m= months; y=years; ADHD= attention deficit hyperactivitiy disorder; ASD = autistic spectrum disorder; EE= epileptic encephalopathy; EEG= electro encephalogram; mod.= moderate; MRI= magnetic resonance imaging; TPM = topiramate; VPA = valproic acid; OFC=occipitofrontal 
Seizures: a = aura; abs = absences; atyp abs = atypical absences; drop at = drop attacks; FDS = focal discognitive seizures; FS = febrile seizures; GTCS = generalized tonic clonic seizures; myo abs = myoclonic absence; myo at = myoclonic atonic; mj = myoclonic jerks; PCS = partial complex seizures; tc = tonic-clonic; PS: photosensitivity
Berryer et al. Hum Mutat 2013 Hamdan et al. Biol Psychiatr 2011 
Vissers et al. 
Nat Genet 
2010
Patient 2 
R0038372
Patient 3 
R0034526
Patient 1 
R0033401
Patient 2 
R0032180
Patient 3 
R0033475
Patient 8 BO14/09
M M F F F F F
4 13 4.4 5.8 12 NA 11
moderate/seve
re
moderate/seve
re
moderate moderate moderate mild/moderate moderate/severe
NA NA NA NA NA 19 m 15 m
17 m 24 M 24 M 21 m 24 m NA 24 m
impaired impaired impaired impaired impaired absent absent
normal normal hypotonia hypotonia normal hypotonia NA
normal normal normal NA NA normal normal
ADHD; 
aggressivenes
s; temper 
tantrums
autism, mood 
instability, 
temper 
tantrums
no ASD no ASD no ASD NA
auto-aggressive 
behaviour
mildly enlarged 
ventricles
NA normal normal normal (TDM)
mild 
myelination 
dealy (10 m)
normal
yes no epilepsy yes yes no epilepsy yes yes
24 NA 15 28 NA 48 26
FS, mj,abs NA
febrile and 
afebrile GTCS; 
PCS
myo at NA NA abs, atonic seizures
good control NA
good control 
by TPM
good control 
by VPA
NA NA NA
bioccipital 
SSW
NA
bioccipital 
spikes during 
light 
stimulation
bioccipital 
spikes during 
light 
stimulation
NA NA NA
Hamdan et al. Am J Hum Genet 2011, New 
Engl J Med 2009 and Biol Psychiatr 2011
Rauch et al. Lancet 2012Hamdan et al. Biol Psychiatr 2011 
Klitten et al. 
Epilepsia 2011
Writzl et al. 
Am J Med 
Genet 2013
Zollino et al. Eur J 
Hum Genet 2011
Krepischi et al. Am 
J Med Genet 2010
ER53899
M M M F M
5 25 9 5 6.8
severe severe moderate severe moderate
17 m NA 10 m NA 6.5 m
36 m 36 m 29 m NA 16 m
absent impaired impiaired impaired impaired
hypotonia NA NA normal NA
normal NA normal normal normal
ADS, stereotypies ASD none ASD, stereotypies NA
arachnoid cyst NA normal normal NA
NA yes yes yes NA
NA 13 48 3 NA
NA
abs, myo abs, 
atyp abs, drop 
at with mj
abs, head 
nodding
myo at, NA
NA poor control
good control 
VPA
positive effect by 
VPA and TPM
NA
NA GSW, GPSW MFD
MFD;SSW; Sp and 
Poly-SPW;  
subcontinuous 
during sleep and 
were reminiscent of 
the EEG features of 
the Lennox–Gastaut 
syndrome
NA
Rauch et al. Lancet 2012
summary
n=35
sex ratio M/F : 0.84
mean 10 y
mild 1; mild/moderate 1; 
moderate 20; 
moderate/severe 5, severe 8 
mean 14.8 m, median 12 m
mean 25.3 m; median 24 m
absent speech 11; single 
words 4; 2-4-word sentences 
3; "impaired" 12
none 6; unsteady gait/ataxia 
8; hypotonia 8 
normal 22; microcephaly (≤ -
2.5 SD) 6
ASD 20; aggressiveness 11; 
stereotypies 5
normal 19; minor nonspecific 
findings 3
yes 26; no 6
mean 30 m; median 24 m; 
75th centile 3.5 years
abs 19; mj 10; drop at 8; tc 4; 
FDS/PCS 4; myo abs 2; 
GTCS 1; PS 1
NA 20; EE 5; poor control 3; 
good control 7
occipital predominance of 
anomalies 8; PS 2
